In a previous paper we described a loss of heterozygosity (LOH) study on the mouse chromosome 4 in g-radiation-induced T-cell lymphomas of (C57BL/ 6J6RF/J) F1 hybrid mice, using polymorphic microsatellites (Santos et al., 1996) . That study suggested the existence of a critical region of LOH of about 0.6 cM between the markers D4Wsm1 and D4Mit9, which is located near to the interferon alpha (Ifa) gene cluster, named as TLSR1 (Thymic Lymphoma Suppressor Region 1). Interestingly, this analysis also provided intriguing preliminary evidence that a more distal chromosome 4 region centered at the D4Mit54 marker, which we named TLSR2 (Thymic Lymphoma Suppressor Region 2), could be the site of another putative tumor suppressor gene. Subsequently, we examined the status of the murine suppressor genes p16
INK4a and p15 INK4b in the same tumors, since they are located on chromosome 4 (Quelle et al., 1995) and because TLSR1 could be the domain of these two genes. This analysis demonstrated frequent allelic losses of the p15
INK4b gene, as well as a strong correlation between transcriptional inactivation and DNA hypermethylation at the p15
INK4b gene, suggesting that this gene has to play an important role in the murine thymic lymphomagenesis (Malumbres et al., 1997) .
The distal part of chromosome 4 region has been implicated by its frequent allelic losses in several tumor types, including 2',3'-dideoxycytidine-and 1,3-butadiene-induced primary lymphomas (Zhuang et al., 1996) , lung tumors induced by vinyl carbamate (Herzog et al., 1995) and mouse mammary tumor virus/v-Ha-ras transgene-induced mammary tumors (Radany et al., 1997) . This region is synthetic to that on human chromosome 1p34-36 (Mock et al., 1996) , which is frequently deleted in dierent cancer types, such as breast tumors (Bieche et al., 1994) , colon cancer (Bardi et al., 1993) , germ cell cancer (Mathew et al., 1994) , gliomas (Bello et al., 1994a) , hepacellular carcinomas (Simon et al., 1991) , leiomyosarcomas (Sreekantaiah et al., 1993) , melanomas (Sokova et al., 1992) , meningiomas (Bello et al., 1994b) , neuroblastomas (Fong et al., 1992) , pancreatic cancer (Ding et al., 1992) , pheochromocytomas (Moley et al., 1992) and thyroid tumors (Khosla et al., 1991) .
In the present study, we carried out a more detailed LOH analysis on the distal part of mouse chromosome 4 in order to con®rm the existence of TLSR2 and to assess its involvement in thymic lymphomagenesis. The screen was designed with three criteria in mind: (a) On the basis of the current map of mouse chromosome 4 (Mock et al., 1996) , we reconsidered the map position of D4Mit205, one of the microsatellites analysed in our previous LOH study; (b) We examined the distal part of chromosome 4 for allelic losses in g-radiationinduced thymic lymphomas from (C57BL/6J6RF/J) F1 (hereafter named B6RFF1) hybrids with a set of microsatellite markers, which were not analysed in that work; (c) We conducted an additional allelotype analysis in g-radiation-induced thymic lymphomas of F1 hybrids, generated from crosses between individuals belonging to the parental mouse strains C57BL/6J and BALB/cJ.
In the above mentioned paper, we analysed for allelic losses 49 g-radiation-induced primary lymphomas of B6RFF1 hybrids with three markers located on the distal part of chromosome 4, D4Mit12, D4Mit54 and D4Mit13. We found 16 tumors with allelic losses aecting these markers. One tumor (R5b) showed LOH only at the D4Mit54 marker, whereas 14 of 15 tumors displayed allelic losses at the three markers. The remaining tumor displayed allelic losses at D4Mit54 and D4Mit13. These results allowed us to de®ne TLSR2 centered at the marker D4Mit54. However, if we now reconsider the map position of the marker D4Mit205 according to the current chromosome 4 map, this microsatellite, renamed as D4Mit205b, is now positioned very close to D4Mit13 (Mock et al., 1996) instead of being located near to the Ifa gene cluster (Abbott et al., 1994) . Then, two tumors (R7a and R15b) would have allelic losses aecting only the distal marker D4Mit205b, and TLSR2 should be de®ned between the markers D4Mit54 and D4Mit205b.
In this work, DNAs from the same 49 tumors were surveyed for LOH using three dierent distal microsatellites D4Mit203, D4Mit68 and D4Mit189) located in close vicinity (proximal or distal) to D4Mit54 or D4Mit205b. No allelic losses at any of these microsatellites were found in tumors R5b (pattern of LOH type I), R7a and R15b (type II) (Figure 1 ). On the remaining cases in which LOH was detected (15 tumors), allelic losses at the three markers were observed (types III and IV). These ®ndings are consistent with the above mentioned observations about the existence of TLSR2.
All these data are in agreement with a previous report that de®ned a critical region of LOH on the distal part of mouse chromosome 4, which lies between markers D4Mit54 and D4Mit13, as a candidate region to contain a tumor suppressor gene for 2'-3'-dideoxycytidine-and 1,3-butadiene-induced mouse primary lymphomas (Zhuang et al., 1996) . Interestingly, D4Mit13 and D4Mit205b have been located in the same map position (71 cM) (Mouse Genome Database, http://www.informatics.jax.org). All this evidence strongly suggests that the chromosome region de®ned by the interval D4Mit54-D4Mit205b/D4Mit13 may contain a tumor suppressor gene that play an important role in mouse lymphomagenesis.
Here also, a total of 81 primary thymic lymphomas induced by g-rays in (C57BL/6J6BALB/cJ) F1 (hereafter named B6BLF1) mice (54 tumors) and the reciprocal strain (BALB/cJ6C57BL/6J) F1 (hereafter named BLB6F1) (27 tumors) were examined for allelic loss by using eight informative distal chromosome 4 microsatellites (D4Mit12, M4Mit203, D4Mit68, D4Mit54, D4Mit158, D4Mit189, D4Mit205b and D4Mit14). Allelic losses were observed in 34 of 81 (42%) thymic lymphomas analysed. Tumors with allele losses were classi®ed in 16 dierent patterns of LOH (types I ± XVI) (Figure 1 ). Of the 15 tumors with more local patterns of allelic losses (types XIII ± XVI), most of them (12 tumors) showed LOH at the marker D4Mit68. Of these, three tumors displayed simultaneous allelic losses at the markers D4Mit203 and D4Mit68 (type XIII), two tumors lost only D4Mit203 Figure 1 Analysis of polymorphic microsatellite markers in g-radiation-induced thymic lymphomas from F1 hybrids de®nes two regions of loss of heterozygosity, TLSR2 (Thymic Lymphoma Suppressor Region 2) and TLSR3 (Thymic Lymphoma Suppressor Region 3) at the distal part of mouse chromosome 4. Allele typings, scoring of losses of heterozygosity (LOH) and the statistical signi®cance of these allele losses were performed as we described previously in Santos et al. (1996) . Microsatellite markers are positioned according to the genetic linkage map data obtained from the Mouse Genome Database. Numbers in brackets indicate the distance in cM of the marker from the centromere. Tumors with allelic losses are classi®ed into 16 patterns of LOH (types I ± XVI). The number of tumors for each type are given in parenthesis. White boxes denote the presence of two of the alleles and black boxes correspond to loss of heterozygosity. Words in black boxes denote the lost alleles: BAL, BALB/cJ; B6, C57BL/6J; RF, RF/J. NI, noninformative; ND, not determined. The black bars de®ne the candidate tumor suppressor regions TLSR2 and TLSR3, respectively. The arrow indicates the proposed relative position at the distal part of chromosome 4 for Mom-1 (Pla2s) (type XIV) (Figure 2a ) and nine tumors showed LOH only at D4Mit68 (type XV) (Figure 2b ). In the remaining tumor allele losses were only seen at the marker D4Mit205b (type XVI) (Figure 2c ). These results allow us to locate more precisely TLSR2 as centered at D4Mit205b, and also reveals the presence of a new critical region of LOH on the distal part of chromosome 4 involved in thymic lymphomagenesis between D4Mit203 and D4Mit68, that we termed TLSR3 (Thymic Suppressor Region 3) (Figure 1) . No preferential allele losses were observed in tumors of any of the reciprocal crosses (B6BLF1 and BLB6F1) (Figure 1 ). This situation clearly constrasts to that observed in thymic lymphomas of B6RFF1 mice, in where a preferential loss of the parental RF/J allele was found (Santos et al., 1996 ; see also Figure 1 in the present study). Thus, genomic imprinting in association with LOH seems to be unlikely involved in thymic lymphomagenesis.
Data reported in this work with thymic lymphomas induced by g-rays, contrast to several other studies that have demonstrated the existence of candidate sites for a tumor suppressor gene on the distal part of mouse chromosome 4 other than TLSR2 and TLSR3. Radany et al. (1997) suggested the presence of a distal site for potential tumor suppressor locus on chromosome 4 in mammary tumors in a region de®ned by the markers D4Mit253 and D4Mit208, which have been mapped distal to D4Mit205b (Mock et al., 1996) . Of interest is that the mentioned allelotype analysis excluded D4Mit54 from the minimum region of LOH, but no markers between D4Mit54 and D4Mit253 were analysed. Thus, this region could overlap with our TLSR2 indicating the presence of the same tumor suppressor locus. On the other hand, ®ndings reported in mouse lung tumors induced by vinyl carbamate Figure 2 Representative allelic loss aecting D4Mit203 (a), D4Mit68 (b) and D4Mit205b (c) markers in thymic lymphomas induced by g rays in F1 hybrid mice generated from crosses between the parental strains C57BL/6J and BALB/cJ. The ®rst three lanes on all three panels represent control DNA samples from the parental strains C57BL/6J (lane 1) and BALB/cJ (lane 2), and from a normal F1 hybrid (lane 3). The remaining 15 lanes (4 ± 18) represent tumor DNA samples. Tumors in lanes 4, 5 and 6 lost D4Mit203 and D4Mit68 markers. LOH only at D4Mit203 occurred in two tumors (lanes 7 and 8), whereas in nine tumors allelic losses were seen only at D4Mit68 (lanes 9 ± 17). Tumor in lane 18 showed LOH only at D4Mit205b Thirty cycles of ampli®cation were carried out as follows: 958C for 1 min, 558C for 1 min and 728C for 1 min. After ampli®cation PCR products were digested with BamHI at 378C overnight. PCR-restriction length fragments were electrophoresed in 12% non-denaturing acrylamide-Tris-HCl, pH 8.8 buered gels, and then silver stained using the BioRad silver stain kit. The ®rst two lanes on this panel represent control DNA from the parental strains C57BL/6J digested with BamHI (lane 1) and not digested (lane 1*). Lanes 2 and 2*, digested and not digested DNA from BALB/cJ. Lanes 3 and 3*, digested and not digested DNA from a normal F1 hybrid. The remaining lanes (4 ± 14) represent tumor DNAs digested with BamHI. Samples in lanes 4 ± 12 are tumors with a pattern of LOH type XV. Lanes 13 and 14, tumors belonging to type XIV. (b) RT ± PCR analysis of Pla2s expression. RNA extracted from normal thymus and small intestine was treated prior reverse transcription with 100 units of DNaseI (Pharmacia) at 378C for 1 h. The same primers designed for the LOH analysis of Pla2s were used in the RT ± PCR analysis. The b-actin mRNA was assayed as control RT ± PCR (see Malumbres et al., 1997) . Ten mg of total cellular RNA were used to generate cDNA in a reaction containing 200 mM dNTPs, 50 mM Tris-HCl, pH 8.4, 6 mM MgCl 2 , 40 mM KCl, 4 mM DTT and a hexanucleotide mix (Boehringer Mannheim). This mixture was heated to 908C for 1 min and 648C for 1 min. One unit of AMV reverse transcriptase (Finnzymes OY) was added and the samples were incubated at 428C for 1 h. One ml of this reaction was used for coampli®cation of the Pla2s and b-actin in a reaction containing 0.2 mM each of the primers for the mentioned two genes, 200 mM dNTPs, 1.5 mM MgCl 2 and 0.5 units of Taq DNA polymerase (Finnzymes OY). Amplication was carried out in 35 cycles consisting of 30 s at 958C, 30 s at 558C and 1 min at 728C. Detection of the RT ± PCR products was performed by direct ethidium bromide staining of the 1.5% agarose gels. All reactions were repeated a minimum of three times Tumor suppressor genes on distal part of mouse chromosome 4 J Santos et al localized a putative tumor suppressor gene to a region centered at markers D4Mit158/D4Mit54 and excluded D4Mit68, D4Mit170 which is proximal to D4Mit205b (Mock et al., 1996) and D4Mit13 from this critical region of LOH (Herzog et al., 1995) . In this case, our data support the notion that TLSR2 and TLSR3 are two tumor suppressor regions clearly distinct from the candidate tumor suppressor locus reported by Herzog et al. (1993) . However, our data could be interpreted dierently without performing multiplex PCR to determine whether homozygous deletion occurred at D4Mit54 in those tumors that appear to contain both alleles of this marker. To address this issue, multiplex PCR was used to comparatively amplify D4Mit54 and a marker locus outside the critical deleted TLSR2 and TLSR3 regions. This marker, Tnfa (located on chromosome 17), was selected since it is ampli®ed to an equivalent extent in both tumor and normal samples. The co-ampli®cation of Tnfa and D4Mit54 alleles was of equal intensity in the critical tumors that de®ne TLSR2 and TLSR3. Taking this evidence together suggests that there may be several tumor suppressor genes residing within the distal part of mouse chromosome 4. This interpretation is consistent with previous observations in human neuroblastoma that suggest the existence of at least three distinct tumor suppressor genes for the human 1p34-36 region (Takeda et al., 1994; Schleiermacher et al., 1994; Cheng et al., 1995) .
A candidate tumor suppressor gene for TLSR2 could be p73, a gene that encodes a protein that shares a considerable homology with the tumor suppressor gene p53, that maps to the 1p36 region frequently deleted in human cancers, and that alterations in its gene expression could contribute to tumorigenesis (Kaghad et al., 1997) . These authors have localized p73 within the interval de®ned by the gene markers TNFR2 (Tumor necrosis factor receptor 2) and CDC2L1 (cell division cycle2-like1). Interestingly, the mouse homologues genes Tnfr2 (75.5 cM) and Cdc2l1 (79.4) de®ne an interval in where D4Mit205b (76.6 cM) has been mapped (Mouse Genome Database). Thus, it is attractive to speculate that TLSR2 could be the site for p73. Nevertheless, further studies will be needed to clone this mouse gene and to determine its involvement in mouse tumorigenesis.
It has been described that the intestinal cancer susceptibility locus Mom-1, which is linked to the suppression of tumorigenesis in mice with multiple intestinal neoplasia (Min) (Dietrich et al., 1993) , is located near to D4Mit68 (0.6 cM distal) (Mouse Genome Database). This fact as well as those findings providing evidence that Mom-1 locus does not appear to undergo mutational alterations in tumors (Dove et al., 1994) indicate that Mom-1 is not a reasonable candidate for TLSR3. However, the boundaries of TLSR3 could change on the basis of variations in the map position of the markers de®ning this region, as it occurred with D4Mit205b and TLSR2. To con®rm the position of Mom-1 with respect D4Mit68 in the genetic map, and to rule out its involvement in lymphomagenesis, we conducted an allelotype analysis of this locus on those tumors de®ning TLSR3 (11 tumors, types XIV and XV) as well as an expression analysis by RT ± PCR with RNA extracted from thymus of normal individuals. The LOH study of Mom-1 was carried out using as a genetic marker a PCR fragment of 136 bp corresponding to the exon 3 of the secretory phospholipase A2 (Pla2s) gene, a candidate for Mom-1 (MacPhee et al., 1995) . We selected the exon 3 because these authors described a polymorphic BamHI site within this nucleotide sequence. Loss of heterozygosity was found in eight of the 11 tumors analysed (six tumors with LOH only at D4Mit68 and two tumors with losses aecting only at D4Mit203), whereas the remaining three tumors (also with LOH only at D4Mit68) failed to detect allelic losses at this gene ( Figure 3a ). These observations establish that the Pla2s gene (Mom-1 locus) should be located between D4Mit203 and D4Mit68 rather than distal to D4Mit68 as it has been previously reported (Mouse Genome Database). The previously described 136 bp cDNA sequence representing a portion of mouse Pla2s RNA was reverse-transcribed from thymus and distal small intestine (used as a positive control) RNA templates. In addition, RT ± PCR of the mouse b-actin mRNA was used as internal control of the RNA quality and ampli®cation. These RNAs were treated with DnaseI prior to ampli®cation to avoid a possible contamination of DNA. No product was recovered from thymus, whereas, as it is expected, Pla2s was only expressed in distal small intestine tissue from BALB/cJ (Figure 3b ). The fact that we found tumors in where LOH does not aect to the Mom-1 locus together with the lack of expression of Pla2s in thymus clearly indicate that Pla2s gene is not involved in thymic lyphomagenesis. Nevertheless, the results obtained from the LOH analysis of Mom-1 locus allow us to make a better de®nition of TLSR3, which now lies between Pla2s and D4Mit68.
